Ziv-aflibercept versus bevacizumab for treatment of CRVO with macular edema..

Comparative study of the efficacy of intravitreal injection between Ziv-aflibercept and Bevacizumab for treatment of central retinal vein occlusion with macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20191205008

Enrollment

Registered

2019-12-05

Start date

2019-12-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central retinal vein occlusion central retinal vein occlusion macular edema central subfield thickness more than 300 micron

Interventions

Ziv&#45

aflibercept 1.25 mg/0.05 ml IVT (intravitreal) of each 28 day cycle X3 cycles and then if is not inclusion criteria&#44

then will consider to reinjection criteria. Location of injection at 3&#45

4 mm away from limbus&#44

and performed with sterile technique. Follow up until mo 6 after 1st injection ,Bevacizumab 1.25 mg/0.05 ml IVT (intravitreal) of each 28 day cycle X3 cycles and then if is not inclusion criteria&#44

and performed with sterile technique. Follow up until mo 6 after 1st injection

Active Comparator Drug,Active Comparator Drug

ziv&#45

aflibercept,Bevacizumab

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: - Diagnosis of CRVO with macular edema - CST > 300 micron (by SD-OCT)

Exclusion criteria

Exclusion criteria: 1. one-eyed patient 2. external ocular infection ex. conjunctivitis , hordeolum and blepharitis 3. diabetic macular edema , age-related macular degeneration, epimacular membrane, vitreomacular traction and macular atrophy 4. History of laser within 6 mo 5. History of intraocular surgery within 6 mo (cataract sx, glaucoma sx) 6. History of intravitreal injection of steroid within 6 mo 7. History of intravitreal injection of anti-VEGF within 8 wk 8. Can't take fundus photo and OCT due to cataract, vitreous hemorrhage, corneal scar and pupillary constriction 9. U/D : myocardial infarction, stroke and uncontrolled HT 10. uncooperative patient ex. spine disease 11. pregnancy / planning of pregnancy within 12 mo 12. can't follow-up

Design outcomes

Primary

Measure	Time frame
visual acuity at the beginning of study and mo 6 ETDRS	—

Secondary

Measure	Time frame
central subfield thickness at the beginning of study and mo 6 by SD-OCT,number of injection at the beginning of study until mo 6 number,adverse effect at pose-dose until mo 6 type	—

Countries

Thailand

Contacts

Public ContactSuthasinee Hemanak

Khonkaen university

golf_golfy1989@hotmail.com66892820249

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026